Torsade de pointes induced by cisapride/clarithromycin interaction.
about
Evidence of impaired cisapride metabolism in neonatesRetrospective analysis of cisapride-induced QT changes in end-stage renal disease patients.Torsades de pointes following clarithromycin treatment.GORD in adults.Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.Review article: cardiac adverse effects of gastrointestinal prokinetics.Use of clarithromycin and roxithromycin and risk of cardiac death: cohort studyMacrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycinRisk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.Drug-induced long QT syndromeThe dog's role in the preclinical assessment of QT interval prolongation.Clinical relevance and management of drug-related QT interval prolongation.Genetic basis of drug-induced arrhythmias.Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?Antimicrobial-associated QT interval prolongation: pointes of interest.Increase in mortality rate following coprescription of cisapride and contraindicated drugs.The genetics of pro-arrhythmic adverse drug reactions.Drug-induced QT-interval prolongation: considerations for clinicians.Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a systematic review of randomized controlled trials.Clinical association between pharmacogenomics and adverse drug reactions.Risk factors for drug-induced long-QT syndrome.Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates.Pharmacogenetics of Adverse Drug Reactions
P2860
Q28362557-75D87B6D-03BF-4714-BE79-42E133A41306Q33145870-DB5FE18A-0EB8-43C5-AF7C-FE5A11335C3AQ33163427-97773B16-A22D-4BFD-AEA2-CCE66F48C30DQ33446555-435F921B-6A40-4C50-AE46-A8A489BF3CF9Q33695220-96FC93F1-14FB-462E-AE7A-F426043961C4Q33792373-E084C3CE-69E3-4F7C-AC6B-4CF872950942Q34041767-3AC06115-2B96-4241-B5B6-C342A5BB05A1Q34049823-B86EA00B-8347-4410-8992-A3B73DBD5887Q34186776-E776EFDA-841C-4968-A248-1E0A54D64125Q34358104-9786BB90-A564-4528-8158-41465E6C0AA9Q35070458-45579301-F52B-4AED-95A6-39BF9CA1B937Q35186542-88A79671-C348-467F-959F-77BCAD6CA3C8Q35791484-DEBEBE29-E269-4ECD-B933-FDFE5A8D653CQ36628026-A660DE10-E42E-4D79-8DFA-133E1EF6EFC3Q36655034-391933D2-9D41-4DA7-9BF1-0F76CC471640Q36765263-6FCEA80A-9063-48C4-A93E-04E914D71B18Q37678040-16F636FD-963A-4118-933C-556BAEA11382Q37767425-047793B4-5E57-4830-BEBD-4DAB7973B26BQ37889655-EBDFDE8C-7DC5-4810-B16C-E89D5974736EQ38431150-72D079A0-B91F-41C8-B6C6-77A64BD39817Q42340044-629B5A28-A222-4BC4-BD41-151477396D2AQ43262191-50484F36-1B16-4DE7-BA16-441420344747Q46981409-C2153778-5069-4657-A71B-013658806A0FQ57302676-B1E3D6F2-D5CF-4EB2-BE29-00F02F7E8C4F
P2860
Torsade de pointes induced by cisapride/clarithromycin interaction.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Torsade de pointes induced by cisapride/clarithromycin interaction.
@en
Torsade de pointes induced by cisapride/clarithromycin interaction.
@nl
type
label
Torsade de pointes induced by cisapride/clarithromycin interaction.
@en
Torsade de pointes induced by cisapride/clarithromycin interaction.
@nl
prefLabel
Torsade de pointes induced by cisapride/clarithromycin interaction.
@en
Torsade de pointes induced by cisapride/clarithromycin interaction.
@nl
P2860
P356
P1476
Torsade de pointes induced by cisapride/clarithromycin interaction.
@en
P2093
R K Piquette
P2860
P356
10.1345/APH.18107
P407
P577
1999-01-01T00:00:00Z